KUALA LUMPUR, Oct 8 (Bernama) -- Curia, a contract research, development and manufacturing organisation, has unveiled its refreshed brand highlighting key capabilities and a personalised approach across small molecules, generic active pharmaceutical ingredients (APIs) and biologics.
“Curia has decades of experience in this industry, and we have continually broadened our capabilities to meet the needs of our customers.
“Our new brand identity clearly communicates not just our offerings, but the unique level of expertise and collaboration we bring as we work to noble purpose to improve patients’ lives,” said Curia Chief Executive Officer, Philip Macnabb in a statement.
This brand update underscores Curia’s role as a dedicated ally to its clients, leveraging over 30 years of industry experience and a robust global presence to accelerate product timelines by addressing both simple and complex challenges across drug discovery, development and manufacturing.
Under the brand refresh, Curia has established brand logos for each of its three key service offerings across small molecules, generic APIs and biologics, in which this new hierarchy of service logos clearly communicates the company’s robust portfolio of services and solutions.
The company has also revamped its website, whereby the evolved design improves the user experience for clients and prospects seeking best-in-class contract development and manufacturing services in small molecules, generic APIs, biologics, analytical services and sterile fill-finish.
Curia began as AMRI more than 30 years ago with a focus on small molecules, and over time, expanded to offer a blend of global resources and scientific expertise. It was rebranded as Curia in 2021 and broadened its capabilities to include biologics with the acquisition of LakePharma and Integrity Bio.
-- BERNAMA
No comments:
Post a Comment